Key result
CardioMEMS improves 1-year net monetary value vs usual care at ~€16,000 per QALY gained.
Why the study?
The value of CardioMEMS for remote pulmonary artery pressure monitoring in heart failure patients within the lower-cost Southern European healthcare setting was uncertain.
Cohort (n=70)
No
Effect estimate: ICER 15,896€/QALY
May support CardioMEMS cost-effectiveness in Spanish HF care; leaves open confirmation via larger randomized trials.
Background: Real-time remote monitoring of pulmonary artery pressures has previously shown to reduce heart failure (HF) related hospitalisations and to improve quality of life of selected HF patients. The value of CardioMEMS in Southern Europe, where healthcare costs are significantly lower, remains uncertain. Objective: To evaluate the cost-effectiveness of the CardioMEMS HF system in the Spanish healthcare setting. Methodology: This single-centre study included 35 HF patients with a CardioMEMS device (treatment group) and compared them with similar patients receiving standard HF treatment (control group). The Propensity Score Matching method was used and the comparators were found using the variables age, sex, New York Heart Association class, left ventricular ejection fraction, and diabetes mellitus. Cost-effectiveness was measured as the incremental cost per quality-adjusted life year gained. Results: The CardioMEMS HF system outperformed usual management with a net monetary value difference of 2,731€ per patient at 1 year. The incremental cost per quality-adjusted life year gained was 15,896€. Results were consistent in the sensitivity analyses performed. Conclusion: This analysis suggests that remote monitoring of pulmonary artery pressure with CardioMEMS HF system is a cost-effective strategy in the Spanish healthcare setting.
No takes yet. Share an insight, caveat, or question.
Codina et al. (2023) conducted a cohort in Heart Failure (n=70). CardioMEMS HF system vs. Standard HF treatment was evaluated on Incremental cost per quality-adjusted life year (QALY) gained (ICER 15,896€/QALY). The CardioMEMS HF system outperformed usual management with a net monetary value difference of 2,731€ per patient at 1 year and an incremental cost of 15,896€ per QALY gained.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: